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Kevin J. Patel, Robert D. Rice, Rebecca Hawke, Michelle Abboud, Glenn Heller,
Andromachi Scaradavou, James W. Young, Juliet N. BarkerPre-engraftment syndrome (PES) occurring after cord blood transplantation (CBT) is poorly characterized.
We reviewed 52 consecutive double-unit CBTrecipients treated for high-risk hematologic malignancies. PES
was defined as unexplained fever .38.3 C (101F) not associated with infection and unresponsive to anti-
microbials, and/or unexplained rash occurring before or at neutrophil recovery. CBTrecipients (median age,
38 years; range, 3-66 years) received either myeloablative (MA; n5 36) or nonmyeloablative (NMA; n5 16)
conditioning. Sixteen patients (31%) fulfilled PES criteria: 15 with fever (median at onset, 39 C [102.2F]), 13
of whom also had rash, and 1 with rash alone. The median onset was 9 days (range, 5-12 days) posttransplan-
tation (a median of 14 days before neutrophil recovery). Sixteen patients (14 with PES and 2 with infection
and possible PES) received intravenous methylprednisolone (median dose, 1 mg/kg; median duration, 3 days);
15 (94%) experienced resolution of fever within 24 hours. Recurrent PES (n5 3) resolved with retreatment.
There was no association between the development of PES and the likelihood of sustained donor engraft-
ment, speed of neutrophil recovery, grade II-IV acute graft-versus-host disease (aGVHD), day-180
treatment-related mortality (TRM), or survival. PES is common after CBT, precedes neutrophil recovery,
is distinct from and does not predict for aGVHD, and responds promptly to short-course corticosteroid
therapy.
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Engraftment syndrome, a clinical entity of unknown
pathogenesis, has been described in patients receiving
both autologous [1-3] and allogeneic [4,5] hematopoi-
etic stem cell transplantation (HSCT). Whereas a uni-
form definition is lacking, one definition, suggested by
Spitzer [6], is a clinical syndrome afterHSCTcharacter-
ized by noninfectious fever, erythematous skin rash, and
pulmonary infiltrates occurring immediatelybeforeor at
neutrophil engraftment. Kishi et al. [7] were the first to
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intensity conditioning (RIC) cord blood transplantation
(CBT). This was associated with variousmanifestations,
including fever, rash, diarrhea, jaundice, and weight
gain. 10% from baseline occurring before neutrophil
engraftment and not explained by infection or adverse
drug reactions. The authors suggested that this pre-en-
graftment syndrome (PES) differs from engraftment
syndrome or acute graft-versus-host disease (aGVHD)
[7]. PES remains poorly characterized, however, and
the prognosis and appropriate management are unclear.
We conducted a retrospective review of 52 consecutive
CBTrecipients treated for high-risk hematologicmalig-
nancies to determine the incidence, manifestations, and
outcomes of PES. Our hypothesis was that PES is dis-
tinct from and does not predict aGVHD.MATERIALS AND METHODS
Patient and Graft Characteristics
This was a retrospective review of 52 consecutive
CBT recipients who received a first allograft at435
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of transplantation complication and outcome data was
sanctioned by the Center’s Institutional Review Board.
Survivors had at least 100 days of follow-up posttrans-
plantation. The patients had a median age of 38 years
(range, 3-66 years) and a median weight of 70 kg
(range, 13-102 kg), and all had a high-risk hematologic
malignancy: acute myelogenous leukemia (AML;
n5 12), acute lymphoblastic leukemia (ALL;
n5 10), acute biphenotypic leukemia (n5 2), non-
Hodgkin lymphoma (NHL; n5 15), Hodgkin lym-
phoma (HL; n5 9), chronic lymphocytic leukemia
(CLL; n5 3), or prolymphocytic leukemia (n5 1).
Patients underwent CBT after receiving either mye-
loablative (MA; n5 36) or nonmyeloablative (NMA;
n5 16) conditioning according to age, extent of previ-
ous therapy, comorbidities, and diagnosis. Cyclospor-
ine-A (CsA) and mycophenolate mofetil (MMF) were
used for GVHD prophylaxis, and all patients received
posttransplantation granulocyte colony-stimulating
factor (G-CSF). All patients received double-unit
grafts to augment engraftment [8,9], with a median in-
fused total nucleated cell (TNC) dose of 2.5 107/kg
(range, 1.42-7.30 107/kg) in the larger unit and
1.9 107/kg (range, 0.91-5.26 107/kg) in the smaller
unit. Units were 6/6 (n5 5), 5/6 (n5 51), and 4/6
(n5 48) HLA-A, -B antigen, and -DRB1 allele–
matched to the recipient, respectively. Donor–recipi-
ent and unit–unit HLA matching also were deter-
mined at high resolution for HLA-A, -B, -C, -DRB1,
and -DQ alleles.
All patients or their parents signed informed con-
sent before transplantation. Patients were hospitalized
in high-efficiency particulate air (HEPA)-filtered single
protective environment rooms and receivedprophylaxis
for fungal infections (including mold), herpes simplex,
and Pneumocystis jiroveci, as well as bacterial infections
during neutropenia. Neutropenic fever was treated
with broad-spectrum intravenous (i.v.) antibiotics.Definition of PES
Medical records were reviewed for clinical features
suggestive of PES and the associated laboratory
and radiologic findings. PES was defined as unex-
plained fever. 38.3 C (101F) not associated with
documented infection and unresponsive to antimicro-
bial manipulations, and/or unexplained erythematous
skin rash resembling that of aGVHD, with either the
fever or the rash occurring before or at neutrophil
recovery. Specifically, fever attributed to PES was
not associated with any clinical evidence of infection,
with patients having both a negative infectious disease
workup and a continued lack of response to broad-
spectrum antimicrobial agents. All patients with fever
underwent an extensive infectious disease workup
that included serial blood cultures (all ports), urinecultures, stool studies (if diarrhea was present), rele-
vant viral polymerase chain reaction (PCR) findings,
and relevant radiologic findings, including lung com-
puted tomography scan. The erythematous skin rash
attributed to PES was not associated with any clinical
suspicion of drug allergy.
Weight gainwas calculated as the percent change in
weight between the day of CBT and the onset of PES.
For comparison, the weight gain in patients with no ev-
idence of PES was calculated as the percent change in
weight between the day of CBT and day 9 posttrans-
plantation (ie, themedian day of onset of PES).Nonin-
fectious diarrhea was defined as passage of liquid stools
more than twice a day for at least 3 consecutive days
with stool studies negative for any infectious etiology.Statistical Analysis
Because there were no early deaths (before day 28
psstransplantation), there were no competing risks in
the calculationofPES incidence.Time toneutrophil re-
covery was defined as the first of 3 consecutive days with
an absolute neutrophil count (ANC). 0.5 109/L af-
ter the first posttransplantation nadir. Sustained donor
engraftment was defined as sustained donor-derived
count recovery with donor chimerism of at least 90%
(both units combined). Overall staging of aGVHD
was based on International Bone Marrow Transplant
Registry criteria [10]. Treatment-related mortality
(TRM)was defined as anydeathnot fromrelapse or per-
sistence of malignancy. Neutrophil engraftment, acute
GVHD (aGVHD), and TRM were computed using
the cumulative incidence function. For neutrophil en-
graftment, the competing risks were autologous recov-
ery, infusion of a backup graft, or death. Graft failure
or death was the competing event for aGVHD, whereas
relapse was the competing event for TRM. Survival was
calculated using Kaplan-Meier methodology. The rela-
tionships between PES outcome and binary, ordinal,
and continuous factors were determined using Fisher’s
exact test, Wilcoxon’s rank-sum test, and the t-test, re-
spectively. The difference in survival rates based on
PES classification was determined using the log-rank
test; the difference in the cumulative incidence curves
was based on Gray’s test.RESULTS
Incidence and Manifestations of PES
Of the 52 patients eligible for analysis, 16 (31%),
including 12 recipients of MA conditioning and 4 re-
cipients of NMA conditioning, fulfilled the diagnostic
criteria for PES. Of these 16 patients, 15 (94%) had
unexplained fever, 13 of whom also had rash. The me-
dian temperature at onset was 39 C (102.2F) (range,
38.4-39.4 C), and fever exhibited a spiking pattern.
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rash alone as the sole manifestation of PES. Although
we originally defined PES as potentially occurring be-
fore or at neutrophil recovery, we found that the me-
dian day of onset of PES was early, at 9 days
posttransplantation (range, 5-12 days). This was a me-
dian of 14 days before neutrophil recovery overall. The
median total white cell count at PES onset was
0 109/L (range, 0-0.9 109/L), with a median
ANC of 0 109/L (range, 0-0.5 109/L). The day
of onset and appearance of symptoms were similar re-
gardless of conditioning.
The remaining 36 patients who did not fulfill strict
PES criteria included 5 patients without posttrans-
plantation fever or rash, 26 patients with fever
secondary to either documented infection or febrile
neutropenia responsive to antimicrobials, and 5 pa-
tiens with fever judged by the treating physician to
be due to infection and possible PES.
The mean weight gain at PES onset was 3% in
both the PES patients and non-PES patients at the
same time point posttransplantation (P5 .60). In addi-
tion, almost half of the patients in each group had non-
infectious diarrhea (P5 1.00). There also was no
significant difference in mean peak bilirubin level
between the 2 groups at days 0-7 (P5 .32), days 8-15
(P5 .29), days 16-21 (P5 .76), or days 22-28
(P5 .54) posttransplantation. Notably, 11 of the 16
PES patients (69%) developed hypoxia and/or pulmo-
nary infiltrates at a median of 12 days (range, 7-15
days) posttransplantation, compared with 16 of 36
non-PES patients (44%) at a median of 12 days post-
transplantation (range, 5-32 days). This difference
was not statistically significant, however (P5 .14).
Human herpesvirus 6 (HHV-6) reactivation may
be associated with fever and rash and is well docu-
mented after CBT [11]. Thus, HHV-6 viremia wasTable 1. Comparison of Patient and Graft Characteristics in PES P
Age, years, mean (range)
Sex, n
Male
Female
Weight, kg, median (range)
Diagnosis, n
Lymphoid malignancy
Myeloid malignancy
Preparative regimen, n
Myeloablative
Nonmyeloablative
Infused total TNC 107/kg, mean (range)
Donor–recipient HLA match, median (range)* 6
Match of better-matched unit 5
Match of lesser-matched unit 6
Unit–unit HLA match, median (range)*
Engrafting unit TNC 107/kg, mean (range)† 6
Donor–recipient HLA match of engrafting unit, median (range)*,†
PES indicates pre-engraftment syndrome; TNC, total nucleated cell.
*Ten allele HLA-A, -B, -C, -DRB1, and -DQ match.
†Excludes 2 patients with graft failure in each group and the single patient whexamined as a potential factor accounting for the man-
ifestations of PES. Fifteen of the 16 PES patients un-
derwent serial assays for HHV-6 virus reactivation
using quantitative PCR of serum, and all were positive.
However, of the 26 patients without PES evaluated, 24
(92%) also had HHV-6 reactivation. In patients with
PES, the mean time to first detection of HHV-6 vire-
mia (.100 copies/mL) was 24 days postransplantation
(range, 10-37 days), notably later than the onset of
PES. This was not different from the mean time to
detection of 21 days in the non-PES patients (range,
10-40 days; P5 .25). The mean peak HHV-6 load
was 22,900 copies in the PES patients (range, 200-
116,000 copies) and 17,100 copies in the non-PES
patients (range, 100-128,000 copies; P5 .58). Thus,
we found no evidence suggesting that the manifesta-
tions of PES can be accounted for by HHV-6.Response to Corticosteroids
A total of 16 patients (14 with PES and 2 with in-
fection and possible PES) received i.v. methylprednis-
olone (MP) to treat PES. The treated patients had high
fever for a median of 5.5 days (range, 3-11 days) before
corticosteroid treatment and received a median dose of
1 mg/kg (range, 0.5-2 mg/kg). All patients treated with
MP responded, as evidenced by resolution of fever
within 48 hours along with resolution of rash. After
the first dose of MP, fever resolved within 12 hours
in 13 of the 16 patients (81%), within 13-24 hours in
2 patients, and within 25-48 hours in 1 patient. Two
remaining PES patients did not receive MP. One of
these patients had rash alone and experienced sponta-
neous resolution within 7 days; the other was not
treated because of concerns about the increased risk
of infection with corticosteroid therapy and remained
febrile for 33 days. Corticosteroid treatment wasatients and Non-PES Patients
PES (n5 16) Non-PES (n5 36) P Value
31 (3-65) 41 (7-63) .08
8 20 .77
8 16
66 (13-108) 71 (22-109) .44
4 10 1.00
12 26
12 24 .75
4 12
4.5 (2.7-12.6) 4.8 (2.6-9.6) .53
/10 (4-8/10) 6/10 (3-9/10) 0.46
/10 (4-8/10) 5/10 (2-9/10) 0.42
/10 (3-10/10) 5/10 (2-9/10) 0.57
2.3 (1.3-5.3) 2.5 (1.4-5.1) 0.51
/10 (4-8/10) 6/10 (2-8/10) 0.90
o was in the no-PES group who engrafted with both units.
Figure 1. Cumulative incidence of grade II-IV aGVHD by day 100 post-
transplantation in PES patients and non-PES patients.
Figure 2. Cumulative incidence of overall survival in PES patients and
non-PES patients.
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the 16 treated patients, 3 had recurrent fever attributed
to PES, which resolved with corticosteroid retreat-
ment (median duration, 10 days; range, 1-27 days).
Patient Demographics and Graft
Characteristics, and the Development of PES
Table 1 compares patient demographics and graft
characteristics of the 16 PES patients and the 36
non-PES patients. There were no significant differ-
ences between the 2 groups in terms of age, sex,
weight, underlying malignancy, or conditioning regi-
men. There also were no between-group differences
in total infused TNC dose, donor–recipient HLA
matching of each CB unit, the unit–unit HLA match,
the infused TNC dose of the engrafting unit, or the
donor–recipient HLA match of the engrafting unit
(at low or high resolution).
PES and Transplantation Outcome
Overall, 3 patients experienced primary graft fail-
ure, and 1 patient experienced secondary graft failure.
Three of these patients receivedMA conditioning, and
1 patient received NMA conditioning. Thus, for the
entire study group the cumulative incidence of sus-
tained donor engraftment was 92% (95% confidence
interval [CI]5 84%-100%), with neutrophil recovery
occurring at a median of 25 days in MA recipients
(range, 13-43 days) and 11 days (range, 7-36 days) in
NMA recipients. Consistent with previous reports
[8,9], engraftment was accounted for by a single unit,
except in 1 patient who had sustained engraftment of
both units.
There was no difference in sustained donor en-
graftment between patients with and without PES,
with graft failure occurring in 2 PES patients and 2
non-PES patients (P5 .58). Excluding the 4 patients
who experienced sustained donor engraftment, in
patients who received MA conditioning, the median
time to neutrophil recovery was 25 days (range, 13-
43 days) in PES patients and also 25 days (range, 14-
33 days) in non-PES patients (P5 .83). In the patients
who received NMA conditioning, these medians were
22 days (range, 7-36 days) in PES patients and 11 days
(range, 7-22 days) in non-PES patients (P5 .35).
For the entire study group, the cumulative inci-
dence of day-100 grade II-IV aGVHD was 40%
(95% CI5 27%-53%). There was no difference in
aGVHD incidence between PES patients and non-
PES patients (44% vs 39%; P5 .79) (Figure 1). The
median time of onset of a GVHD was 50 days (range,
34-70 days) in the PES patients and 41 days (range, 29-
99 days) in the non-PES patients.
For the entire group, TRM at day 180 was 24%
(95% CI5 13%-35%). Four PES patients and 4
non-PES patients died from transplantation-relatedcauses by day 180 (P5 .23). With a median follow-
up of 12 months (range 1-36 months), the 1-year over-
all survival (OS) was 64% (95% CI5 52%-80%).
There was no difference in OS between PES patients
and non-PES patients (61% vs 62%; P5 .43)
(Figure 2).DISCUSSION
PES has been well described after autologous
transplantation, although the reported incidence is
highly variable depending on the definition used [6].
ES after allogeneic transplantation is less well under-
stood, with some investigators attributing it to hyper-
acute aGVHD [6]. Interestingly, a number of early
reports on CBT described an onset of aGVHD well
in advance of neutrophil engraftment. For example,
Sanz et al. [12] described a median time to onset of
aGVHD of 9 days (range, 4-14 days) with a median
time to neutrophil recovery of 22 days (range, 13-52
days) [12]. Furthermore, while Wagner et al. [13]
reported a median onset of aGVHD of 35 days
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days posttransplantation. It is likely that some patients
with this ‘‘early aGVHD’’ may have had PES. Kishi
et al. [7] defined a pre-engraftment immune reaction
in reduced-intensity single-unit CBT recipients that
included the presence of fever, skin eruption, diarrhea,
jaundice, and weight gain. 10% of baseline that could
not be attributed to infection or adverse effects of med-
ications. These broad criteria likely accounted for the
high incidence of 78% of PES reported in their study.
Using a stricter definition of unexplained noninfec-
tious fever and/or unexplained skin rash, we found
that 31% of our CBT patients fulfilled the criteria
for PES. This indicates that this syndrome, as with al-
logeneic transplantation using other stem cell sources
[6], is relatively common. On the other hand, our strict
definition may have led to an underestimation of this
syndrome. We excluded 5 patients who were judged
by the treating transplantation physician to be in-
fected; these patients also could have had PES (espe-
cially because 2 of them were treated with and
responded to corticosteroids).
The onset of PES in our CBT series was identical
to that described by Kishi et al. [7], a median of 2 weeks
before neutrophil recovery, clearly justifying the term
‘‘pre-engraftment.’’ Interestingly, we found that
weight gain, hyperbilirubinemia, and noninfectious
diarrhea were no more frequent in the PES patients
than in the non-PES patients. The difference between
the 2 groups in terms of hypoxia and/or pulmonary in-
filtrates also was not significant. Nonetheless, the tem-
poral correlation with the development of pulmonary
manifestations following the onset of unexplained
fever in patients with PES merits further study. Such
investigation may be hampered by our incomplete
knowledge of the etiology or predisposing factors to
the syndrome, however.
The development of PES in autologous and allo-
geneic BMT recipients has been associated with
a wide variety of risk factors. In studies of autologous
transplantation, predisposing factors included specific
diagnoses [3,14], less extensive previous therapy [14],
busulfan (Bu)-based conditioning [2], a greater num-
ber of infused hematopoietic cells [2,15], use of G-
CSF [1], and early and steep neutrophil recovery [2].
In the allogeneic setting, Gorak et al. [4] described
older age, female sex, and the use of amphotericin for-
mulations as predisposing factors for PES after NMA
conditioning. Schmid et al. [5] also reported treatment
with amphotericin, use of G-CSF, and grafts with
higher cell doses as risk factors for PES in pedatric al-
lograft recipients. In contrast, we found no significant
differences between patients with and without PES in
terms of age, sex, conditioning regimen, infused cell
dose, or HLA match. We also found that PES could
not be attributed to HHV6 virus reactivation. Thus,the mechanism and predisposing factors for this rela-
tively common syndrome after CBT remain unknown.
Although corticosteroids have been used to treat
ES after autologous HSCT [1-3,14] or allogeneic
HSCT [4,5] as well as pre-engraftment immune reac-
tions in CBT recipients [7,16], there is no agreement
about the correct dose or treatment duration. All of
the PES patients in this study treated with corticoste-
roids responded rapidly, with most fevers resolving
within 12 hours. It is interesting to postulate that
PES may have become more frequent since the aban-
donment of corticosteroids as GVHD prophylaxis by
many centers. But, this does not warrant the use of ei-
ther corticosteroids (with their associated infection
risk) or methotrexate (with its associated risk of de-
layed engraftment) [16] as preventative therapy for
PES after CBT, given that this syndrome is profoundly
steroid-sensitive. Furthermore, although the majority
of patients did not experience recurrent PES, the 3 pa-
tients who did so responded promptly to retreatment.
More importantly, there was no association between
PES and the subsequent development of aGVHD,
with a median day of aGVHD onset of 50 days post-
transplantation in PES patients. Clearly, a detailed
workup to exclude infection is mandatory in CBT
recipients being considered for PES. However, for
those patients meeting the criteria for PES (pre-
engraftment, without documented infection, no
response to broad antimicrobial coverage, and no
other features such as progressive gut or liver pathol-
ogy, suggesting aGVHD), a reasonable approach is
to diagnose PES and provide treatment with short-
course corticosteroids, and not diagnose early
aGVHDpredating engraftment. Although the optimal
therapy for PES is unknown, and no definitive recom-
mendations can be made based on a relatively small se-
ries, we are now investigating 1 mg/kg/day of i.v.
methylprednisolone for 3 days with no taper and close
monitoring for patient well being after corticosteroid
cessation.
One further aspect of PES after CBT deserves em-
phasis. Whereas we did not find increased mortality in
our PES patients, PES is associated with significant
morbidity. Failure to recognize this syndrome in
CBT recipients risks unnecessary complications of
high fevers with possible pulmonary complications,
as have been seen in autologous transplant recipients
with PES. Prompt recognition of PES and treatment
with a short-course corticosteroid regimen also can
help avoid unnecessarily long, empiric courses of treat-
ment that could promote opportunistic infections.
Thus, further validation of our findings in a prospective
investigation of a larger series of CBT recipients is
warranted. This should include studying the incidence
of PES to ascertain whether there are differences be-
tween recipients of single-unit and double-unit CBT,
440 Biol Blood Marrow Transplant 16:435-440, 2010K. J. Patel et al.characterizing associated end-organ toxicities (espe-
cially possible pulmonary manifestations), and, most
importantly, searching for biomarkers that may pro-
vide clues to etiology [17].ACKNOWLEDGMENTS
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